Science Blog

Articles by Dudley Tabakin

Dudley Tabakin

Dudley Tabakin, MSc. is CEO and co-founder of VivoSense and a fervent believer in “good data” over “big data" in the development of digital endpoints from wearable sensor technology.

Find me on:

Measuring Respiratory-related Outcomes with Wearable Sensors

Posted by Dudley Tabakin on April 8, 2021

Respiratory abnormalities characterize a variety of disorders. In addition to physical disorders, ventilation is profoundly affected by mental and psychophysiological states, including stress, anxiety, and panic disorder. Let’s take a look at the highlights of respiratory-related health issues and the promising wearable technology available to assess respiratory outcome measures in real-world settings.

Read More

Digital Health Technologies in Clinical Drug Development

Posted by Dudley Tabakin on February 16, 2021

Digital health technologies have the potential to transform clinical drug development. They can collect continuous, high-resolution data in patients’ real-world environments for extended periods of time, providing researchers with an unprecedented level of insight into patients’ physiological and behavioral states. These types of data may more accurately describe a patient’s experience and enable previously unattainable scientific undertakings.

Read More

Guide to the Shared Foundation for Digital Clinical Measurement

Posted by Dudley Tabakin on November 24, 2020

To drive scientific progress and increase digital medicine acceptance, the Digital Medicine Society (DiMe) has created The Playbook: Digital Clinical Measures, the essential industry guide for successfully developing & deploying digital clinical measures across clinical research, clinical care, and public health.”

We are excited to be included in the Tour of Duty, a team of experienced tech, pharma, clinical leaders, regulators, and patient advocates driving the adoption of a shared foundation for the digital health field.

Read More

VivoSense Awarded NIH/NCI Grant to Aid in Cancer Research

Posted by Dudley Tabakin on October 15, 2020

VivoSense, Inc. is proud to announce that we have been awarded an NIH/NCI Phase 1 contract to develop software enabling data integration from wearable sensors for cancer patients. The contract will result in the development of the VivoSense Cancer Health Informatics Platform as the leading wearable sensor agnostic cloud platform for cancer research and clinical care.

Read More

New Release: VivoSense® Software 3.5 for Wearable Sensor Data Analysis

Posted by Dudley Tabakin on August 20, 2020

As the leading provider of visualization and analysis software for data from wearable sensors, we are committed to continually improving VivoSense and expanding its capabilities for our academic research partners. Here are some of the highlights of our recent release of VivoSense® 3.5.

Read More

Developing Digital Biomarkers Post Covid-19

Posted by Dudley Tabakin on July 9, 2020

The 3rd Annual Digital Biomarkers in Clinical Trials Summit hosted by Roche was the virtual place to be in June, bringing together 250+ global thought leaders and experts. They shared insights on developing and improving the way pharma clinical trials utilize mobile-enabled, wearables, and IoT capabilities to augment existing biomarker strategies, improve patient experience, and collect better data.

Read More

Benefits of Using Wearable Sensors in Clinical Trials

Posted by Dudley Tabakin on June 26, 2020

The study of human health in real-world, everyday environments is necessary to advance knowledge and discovery. Wearable sensors make this possible by providing customized body-worn monitoring and analysis solutions that are rooted in scientific foundations. Here’s an infographic highlighting the advantages using wearable technologies in your clinical trials.

Read More

Good Data is Essential in Digital Biomarker Development

Posted by Dudley Tabakin on June 4, 2020

Good data is more important than big data in the development of digital biomarkers. Big data is often sold as the solution to all digital data analyses and touted to revolutionize healthcare in the coming years. However, the problem with a superabundance of data is that digital biomarker development becomes a fishing expedition, and the catch may not be relevant to the question. Without a hypothesis (often the case in biomarker development with big data), accurate results may be too low to use in a clinical trial, or even worse, divergent with no findings.

Read More

US Marine Corps Studies HRV to Predict PTSD Using Wearable Sensor Data

Posted by Dudley Tabakin on May 14, 2020

Here’s an example of how a clinical research team used hypothesis-driven research methods to discover HRV (Heart Rate Variability) associations with stress disorder symptoms in Marines. VivoSense® software was used to analyze the data collected, ensuring that unusable artifactual data was removed to allow for more accurate findings.

Read More

An Introduction to the Foundation of Digital Biomarker Development

Posted by Dudley Tabakin on April 9, 2020

The future of clinical trials involves real-world data collected from wearable sensors and connected technologies. Pharmaceutical companies are investing heavily in digital innovation; however, the adoption of digital biomarkers remains slow. To overcome the challenges associated with high frequency, real-world data, and for digital solutions to realize their potential in clinical trials, we must develop robust and systematic approaches to their use.

Read More

Subscribe to Email Updates

Stay Connected

Popular Articles